JCO Article Insights: Simultaneous Durvalumab and CRT in Unresectable Stage III NSCLC

Health Outcomes in Older Childhood Cancer Survivors

Long-Term Remission After Cilta-cel in Patients With RRMM

JCO Article Insights: Xevinapant Plus Chemoradiotherapy in Unresected LA SCCHN

Income Among Adolescents and Young Adults Surviving Cancer

JCO Article Insights: Phase I DLL3/CD3 T-Cell Engager in DLL3-Positive SCLC or NECs

TTFields in Locally Advanced Pancreatic Adenocarcinoma

JCO at WCLC: Multinational Pivotal Study of Sunvozertinib in Exon20ins NSCLC

Racial and Ethnic Disparities Among Medicare Beneficiaries

JCO Article Insights: Lymph Node Dissection for Lung Cancer

JCO Article Insights: IMS-IMWG Consensus on High-Risk Multiple Myeloma

JCO Article Insights: Pooled Taletrectinib Efficacy and Safety

JCO at ASCO Annual Meeting: Neoadjuvant Osimertinib for Resectable EGFR-Mutated NSCLC

JCO at ASCO Annual Meeting: Use of Low-Value Cancer Treatments in Medicare

JCO at ASCO Annual Meeting: Avelumab Plus Cetuximab vs. Avelumab in Advanced cSCC

JCO at ASCO Annual Meeting: TTFields in Locally Advanced Pancreatic Adenocarcinoma

JCO at ASCO Annual Meeting: Lenvatinib Plus Pembrolizumab and Chemotherapy in Gastric Cancer

JCO Article Insights: Double Hit Myeloma Correlates With Adverse Patient Outcome

Pembrolizumab and Bevacizumab for Melanoma Brain Metastases

JCO Article Insights: ESPAC4 Long-Term Follow-Up in Pancreatic Cancer